Participants must meet all following inclusion criteria:  diagnosed with any psychotic disorder, which can include schizophrenia, schizoaffective disorder, bipolar disorder with psychotic features, delusional disorder, psychotic disorder not otherwise specified, brief psychotic disorder and substance-induced psychotic disorder; has been followed at an early psychosis clinic for a minimum of 3 months; currently using cannabis (at least one time in the past 4 weeks); is open to changing cannabis-related practices; able to provide full informed consent; available for the whole study duration and able to comply with study procedures; able to comprehend French or English.  Participants are excluded if any of these exclusion criteria is met:  pregnancy, nursing or any medical condition that in the opinion of the psychiatrist precludes safe participation in the study or the ability to provide fully informed consent; any disabling, unstable or acute mental condition that in the opinion of the psychiatrist precludes safe participation in the study or the ability to provide fully informed consent; any legal/judicial status/issue, pending legal action, or other reasons in the opinion of the study team that might prevent completion of the study; presence of a substance use disorder that, in the opinion of the psychiatrist, precludes safe participation in the study (e.g., very unstable or severe substance use disorder); currently seeking psychological or pharmacological treatment for cannabis use disorder to cease or decrease his/her use; currently participating in another specific cannabis-focused intervention.